IV Safety Company ivWatch Attending MEDICA Conference in Düsseldorf November 13 – 16, 2023

Company to showcase patented IV safety technology at leading European B2B medical trade fair

NEWPORT NEWS, Va. — October 30, 2023  ivWatch, LLC, the IV safety company, today announced its participation in MEDICA 2023, where it will exhibit its patented biosensor technology which is being increasingly adopted in Europe and the UK. The company has seen an increased demand for its products in the region due to growing awareness of IV infiltration and extravasation injuries and as healthcare decision makers place emphasis on preventing them. Its booth is located in Hall 16, space C20.

ivWatch is the inventor and manufacturer of the only FDA-cleared and CE Marked continuous IV site monitoring technology, and it recently more than doubled new patent grants in Europe and Israel. The company’s robust patent portfolio has expanded to 69 patents around the world protecting its core technologies and reinforcing its commitment to current and future innovations. The medical device technologies work as a monitoring system to notify clinicians in real time of an IV infiltration or extravasation, which helps reduce patient harm and improve outcomes in IV therapy.

The ivWatch system has been clinically tested in laboratory and real-world settings across Europe.

In a new study conducted by Gemelli University Polyclinic in Rome published in The Journal of Vascular Access (JVA), the continuous IV monitoring system was deployed to identify the leakage of intravenous infused fluids in infants receiving infusions by the peripheral route. The study found that continuous infusion site monitoring using the ivWatch system detected an 80% infiltration rate. This infiltration rate is an unfortunate normal in neonatal units, significantly higher than other hospital unit’s infiltration rates. The study found an overall sensitivity of 88.9% in detecting infiltration before the clinician, where the clinician is considered the gold standard. On average, infiltration events were detected six hours prior to a clinical diagnosis.

A new study published in The Journal of Vascular Access (JVA) examines the monitoring of infiltrations and extravasations in a 24-bed neonatal intensive care unit (NICU) at Wilhelmina Children’s Hospital, part of the University Medical Centre of Utrecht in the Netherlands. It found that continuous infusion site monitoring using the ivWatch system detects PIVIE events earlier rather than relying on intermittent visual observation alone, and that detection occurred in 100% of leakage events prior to a clinician detecting such an event. During the monitoring time of the study with ivWatch technology, 11 infiltrations were detected in 21 monitored PIVCs, which corresponds to a 52.4% infiltration incidence rate.

With over 4,500 exhibitors from 66 countries and more than 81,000 visitors from all over the world, MEDICA is one of the largest medical B2B trade fairs in the world. A wide range of innovative products and services from the fields of medical imaging, laboratory technology, diagnostics, health IT, mobile health as well as physiotherapy/orthopedic technology and medical consumables are presented. The extensive program of first-class forums, conferences and special shows provides opportunities for interesting presentations and discussions with experts and politicians and also includes pitches of new products and award ceremonies.

To schedule an appointment to speak with ivWatch executives at the event, please book your appointment here, Monday, November 13 through Thursday, November 16 from 9AM – 6PM. To learn more about the ivWatch patient monitoring system for IV infiltrations and extravasations visit: https://www.ivwatch.com/tech-overview/.

About ivWatch, LLC
ivWatch, LLC  is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, Instagram @ivWatchLLC and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.


Meet us at NICA | June 21st - June 22nd | **BOOK TODAY**
Meet us at NICA | June 21st - June 22nd | **BOOK TODAY**